Physician profile
Natalie Cher
NPI 1538227251
$2,831.96
in general payments reported to CMS, 2019-2025
24 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $599 · 2021: $341 · 2022: $393 · 2023: $349 · 2024: $391 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $297.69 | 2019-2024 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $296.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $271.79 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $262.18 | 2020-2025 | Verquvo, Steglatro |
| Abbott Laboratories | $212.67 | 2019-2021 | |
| Glaxosmithkline, LLC. | $200.27 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $194.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $183.18 | 2020 | |
| Daiichi Sankyo INC. | $174.38 | 2021-2024 | Injectafer |
| Novo Nordisk INC | $149.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $83.93 | 2021-2022 | |
| Boston Scientific Corporation | $71.48 | 2024-2025 | Watchman Flx |
| Lilly USA, LLC | $71.21 | 2022-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $61.92 | 2020-2022 | |
| Pfizer INC. | $44.19 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.02 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $41.69 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $32.33 | 2024 | Assure Wcd |
| United Therapeutics Corporation | $30.68 | 2025 | Tyvaso |
| Corcept Therapeutics | $28.50 | 2024 | Korlym |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.68 | 2024 | Lifevest |
| Sanofi Pasteur INC. | $21.66 | 2022 | |
| Phadia US INC. | $17.91 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $16.79 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Cher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.